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controls, model group, the drug groups were administrated
with Vit E (10mg/kg, ip.) and CAPE (3mg/kg, 6mg/kg,
12mg/kg, ip. & 12mg/kg, 24mg/kg, ig.) daily throughout
10 weeks. At the end of the experiment, GSH, SOD and MDA
levels and CAT activity of liver homogenate were quantiﬁed.
Excised liver tissue was taken to undergo HE and Van Gieson
staining.
Results: Data showed decrease in MDA level and increase
in GSH, SOD levels, and CAT activity in the CAPE
treated groups, compared with model group. There were
statistically signiﬁcant difference between CAPE (12mg/kg,
6mg/kg, via ip route) groups and model group (p < 0.05),
and the other CAPE treated groups were not. What’s more,
treatment with CAPE attenuated the inﬂammation and
ﬁbroplasias induced by CCl4, alcohol and high-lipid forage.
In conclusion, CAPE protects against CCl4, alcohol and
high-lipid forage induced oxidative stress, and enhances
antioxidant capacity. In addition, intraperitoneal injection
is the better way to produce the best pharmacodynamic
effects.
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Background: The progressing increasing of hypoxia inducible
factor-1alpha (HIF-1a) and HIF-1amRNA were found during
the malignant transformation of hepatocytes in our previous
work. In this study, the expression of hepatic HIF-1a
and level of its gene transcription were investigated in
different tissues of human hepatocellular carcinoma (HCC)
for exploring the relationship between HIF-1a expression
and HCC development.
Methods: The alterations of liver HIF-1a transcription
and expression were observed through the self-controlled
specimens from 35 human HCC patients. The expression
and cellular distribution of hepatic HIF-1a were analyzed
by immohistochemistry. The gene fragments of HIF-1amRNA
in different liver tissues were ampliﬁed by nested-PCR, and
conﬁrmed by sequencing.
Results: The positive HIF-1a was brown and granule-
like, mainly presented in cytoplasm and few in nucleus.
The incidence of HIF-1a expression was 80% (28/35) in
HCC, and 100% (35/35) in their paracancerous tissues,
respectively. The speciﬁc concentrations of total RNA were
12.4±7.3mg/mg wet liver in HCC and 53.8±52.0 mg/mg
wet liver in their paracancerous tissues (t = 3.05, P < 0.01).
The clinical pathological features of HIF-1a expression
demonstrated that no signiﬁcant correlation was found
between HIF-1a and tumor numbers, differentiation degree
or positive-HBsAg except of tumor size.
Conclusion: Hepatic HIF-1a expression is associated with
development and prognosis of HCC, and should be an
attractive molecular-target for HCC therapy.
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Background: Hepatocellular carcinoma (HCC) prognosis is
poor and early diagnosis is of the utmost importance.
The objective of this study was to investigate the
dynamic expression of glypican-3 (GPC-3) and its gene in
hepatocarcinogenesis, the relationship of its expression with
HBV infection, and diagnostic values for HCC.
Methods: The characteristics of GPC-3 expression were
observed by rat hepatoma models. Liver GPC-3 Expression
was analyzed by immunohisto-chemistry or Western
blotting. Hepatic GPC-3 mRNAs were extracted and
ampliﬁed by using a nested polymerase chain reaction (PCR)
or real-time PCR assay. The ampliﬁed fragments of GPC-3
gene were conﬁrmed by DNA sequencing. The level of serum
GPC-3 in patients with liver diseases was quantitatively
detected by an ELISA method.
Results: The dynamic alteration of GPC-3 was conﬁrmed by
hepatoma models with brown granule-like staining localized
in membrane and cytoplasm in morphological stages of
granule-like degeneration, atypical hyperplasia and cancer
formation. Of self-control human HCC tissues, the incidence
of GPC-3 was 80.6% in HCC, 41.7% in their surrounding,
and none in distant group (c2 = 11.445, P < 0.000) with no
signiﬁcant relationship between GPC-3 and differentiation
grade or tumor number except of tumor size (Z = 2.941,
P = 0.003); and the features of circulating GPC-3 was
detected in only HCC patients (52.8%) without signiﬁcant
different between GPC-3 and sex, age, AFP, tumor number,
Child-pugh classiﬁcation or extrahepatic metastasis except
of size (c2 = 6.318, P = 0.012) and HBV infection (c2 = 23.362,
P < 0.000). Combined analysis of GPC-3 and AFP levels could
rise up to 87% for HCC diagnosis.
Conclusions: Abnormal expression of hepatic and circulating
GPC-3 may be associated closely with occurrence of HCC
and could be a useful speciﬁc molecular marker for HCC
diagnosis.
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Background: Chronic hepatitis B (CHB) is a severe
liver disease and can progressively develop hepatic
ﬁbrosis. Notably, high levels of tissue inhibitor of
metalloproteinases-1 (TIMP-1) expression are observed
in patients with liver ﬁbrosis. However, the potential
relationship between the levels of serum TIMP-1, hepatic
TIMP-1, and the degrees of hepatic ﬁbrosis in patients with
CHB has not yet been illustrated. This study aimed at
investigating the relationship between TIMP-1 expression
and liver ﬁbrosis severity in patients with CHB.
Methods: In the present study, a total of 159 CHB
with varying degrees of liver ﬁbrosis were recruited and
subjected to liver biopsy for the analysis of their liver
ﬁbrotic stages and inﬂammatory activities. The levels of
TIMP-1 expression in the liver tissues and serum TIMP-1 in
those patients were determined by immunohistochemistry
and enzyme-linked immunoabsorbent assay (ELISA),
respectively.
Results: Our results indicated that the concentrations of
serum TIMP were positively correlated with the levels
of TIMP-1 expression in the liver tissues (R = 0.9521) and
the degrees of liver ﬁbrosis (0.704) in CHB patients
with inﬂammation at grade 2. More importantly, the
concentrations of serum TIMP-1 were independent of the
degrees of inﬂammation in those patients.
Conclusion: Our ﬁndings suggest that the TIMP-1 may be a
valuable biomarker, and that the detection of serum TIMP-1
concentrations may be a safe and cost-effective measure
for the evaluation of liver ﬁbrosis at least in CHB patients.
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